# OnCo record paper-elevate-tn-acalabrutinib-lancet-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-elevate-tn-acalabrutinib-lancet-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-elevate-tn-acalabrutinib-lancet-2020" ;
  schema:name "ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL"@en ;
  schema:description "In ELEVATE-TN, acalabrutinib, a second-generation BTK inhibitor, with or without an antibody, cut the risk of progression by 80-90% compared with chlorambucil-obinutuzumab in older or unfit patients with CLL."@en ;
  schema:url <https://onco.cc/key-papers/paper-elevate-tn-acalabrutinib-lancet-2020/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=ELEVATE-TN%20acalabrutinib%20obinutuzumab%20chlorambucil%20Sharman%20Lancet%202020>, <https://clinicaltrials.gov/study/NCT02475681> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(20)30262-2> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Sharman JP, Egyed M, Jurczak W, et al." ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/cd20/> ;
  onco:drugs <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/zanubrutinib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/pfs/> ;
  onco:trials <https://onco.cc/trials/elevate-tn/>, <https://onco.cc/trials/sequoia/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-drug-pricing/> ;
  onco:journals <https://onco.cc/journals/lancet/> .